Biocon Biologics Ltd., a biosimilars firm and subsidiary of Biocon Ltd., on Monday, said it has got a licence from US-based Adagio Therapeutics for an antibody therapy to treat and prevent COVID-19, for India and select markets. Adagio Therapeutics has granted an exclusive licence to the company to manufacture and commercialize an antibody treatment based on ADG20 for India and select emerging markets, Biocon Biologics said in a statement.

This partnership with Adagio, "aligns our joint vision of bringing superior biologic therapies to millions of patients in low and middle-income countries," Kiran Mazumdar, Executive Chairperson, Biocon Biologics Ltd, said.

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related covid-19, was in global clinical development by Adagio as a single agent for both the treatment and prevention of COVID-19, the disease caused by the SARS-CoV-2 virus, its variants, as well as future variants that may emerge, it said.

The Executive Chairperson, Biocon Biologics Ltd, added: This partnership with Adagio aligns our joint vision of bringing superior biologic therapies to millions of patients in low and middle-income countries. Vaccines alone will not protect and make the world safer. Biologic therapies that arrest the virus in its path of devastation are a necessity for sustainable protection and safety.”

Study reveals- Vaccination gives 97.4 pc protection from COVID-19

Scientists give warning on Resurgence of Respiratory Viruses in Young Children

How new Atlas charts antibodies attack spike protein of Covid variants